|Articles|March 8, 2022
- Pharmaceutical Executive-03-01-2022
- Volume 42
- Issue 3
Pharmaceutical Executive, March 2022 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive March 2022 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 4 years ago
Pressed Into Action: Measuring Pharma’s Reputation Reversalabout 4 years ago
Biopharma in 2021: Big Gains, Volatile Valuesabout 4 years ago
The Resilience of R&D: Pharma Posted Record Output in 2021about 4 years ago
New Age of Psychedelicsabout 4 years ago
Roads Less Traveledabout 4 years ago
Biopharma Stocks, M&A Sputter Amid More Headwindsabout 4 years ago
Pandemic Accelerates CTV Ascent: How Pharma Can Benefitabout 4 years ago
The Human Factor in Data Security Breachesabout 4 years ago
Tapping the Surge in Useful Contingent Labor MarketNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Travere Therapeutics’ Filspari Receives Full FDA Approval
2
Regeneron Enters $2.1 Billion Radiopharma Collaboration with Telix Pharmaceuticals
3
FDA Issues CRL to Replimune for RP1 Biologics License Application for Advanced Melanoma Treatment
4
Managing Patient Experience and RWE in Clinical Trials: Q&A with Matt Holms, MB
5